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ABSTRACT - Purpose: The objective of this work was to evaluate the effect in the immune response 
produced by CpG oligodeoxynucleotides (ODN) co-encapsulated with the antigen ovalbumin (OVA) within 
poly(lactic-co-glycolic) acid (PLGA) 502 and 752 microparticles (MP). Methods: MP were prepared by 
blending 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) with PLGA and Total Recirculation One 
Machine System (TROMS) technology and contained OVA along with CpG sequences associated to 
DOTAP. After confirming the integrity of both encapsulated molecules, BALB/c mice were immunized 
with the resulting MP and OVA-specific antibodies and cytokine production were assessed in order to 
determine the immunological profile induced in mice. Results: One m near non-charged MP co-
encapsulated very efficiently both OVA and CpG ODN. The release of both OVA and CpG was slow and 
incomplete irrespective of polymer. The results of the immune response induced in BALB/c mice indicated 
that, depending on the PLGA polymer used, co-encapsulation did not improve the immunogenicity of the 
antigen, compared either with the simply co-administration of both antigen and CpG, or with the 
microencapsulated antigen. Thus, mice immunized with OVA associated to PLGA 756 displayed an IgG2a 
characterized response which was biased to an IgG1 profile in case of CpG co-encapsulation. On the 
contrary, the co-encapsulation of CpG with OVA into PLGA 502 significantly improved the isotype shifting 
in comparison with the one showed by mice immunized with OVA loaded PLGA 502. Conclusion: This 
study underlines the importance of MP characteristics to fully exploit simultaneous antigen and CpG ODN 
particulate delivery as effective vaccine construct. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
____________________________________________________________________ 
 
INTRODUCTION 
 
Modern vaccine formulations are steering away 
from live attenuated viruses and bacterial toxoids 
to more defined and purified recombinant sub-
unit proteins. However, these antigens are often 
poorly immunogenic due to lack of an innate 
immune stimulus and need an adjuvant to obtain 
an effective immune response. Poly(lactic-co-
glycolic) acid microparticles (PLGA MP) are 
promising vaccine adjuvants (1). The 
immunoadjuvant properties of particulates were 
classically ascribed to enhanced phagocytic 
uptake of encapsulated antigen by antigen 
presenting cells (APC) and more recently to 
NALP3 inflammasome activation (2). This 
mechanism of action is shared with other 
particulates as Alum or the emulsion MF59
®
, 
currently authorized for human vaccines (3). 
 Although the shaping of specific immune 
response by Nucleotide-binding oligomerization 
domain-Like Receptors (NLR) activation is not  
 
well-defined yet (4, 5), it seems that particulate 
adjuvants are less-effective in promoting Th1-
type immune responses than Toll-Like receptors 
(TLR) ligands such as i.e. CpG ODN 
(oligodeoxynucleotides) or monophosphoryl lipid 
A (6, 7). TLR agonists, discovered twenty years 
ago, showed great potential and extreme 
versatility as vaccine adjuvants (8). However, 
concerns about security and potential risk of 
autoimmune disorders have hindered their 
approval in licensed products (9, 10). 
 Therefore, the use of particles as carriers for 
both antigen and TLR agonists has been proposed 
as an “ideal” sub-cellular and well-defined 
vaccine model (11, 12). 
________________________________________ 
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The combination of particulate formulation with 
TLR agonists can enhance vaccine efficacy 
because of the synergistic and simultaneous 
activation of TLR and NLR signalling pathways 
(13). Moreover, the particulate delivery can 
selectively target TLR agonists to APC, avoiding 
their rapid spread into the body and off-target 
toxic effects (14). 
 The clinical emplacement of MP as 
immunoadjuvants has still to overcome several 
drawbacks. Some of them, such as the entrapment 
the antigen within MP without loss of 
antigenicity, as well as the challenge of ensuring a 
consistent quality of the formulation, are been 
surmounted with new fabrication technologies. 
Therefore, there is a big hole in the knowledge of 
the influence of particles physicochemical 
characteristics as size (15, 16), composition, 
antigen release kinetic (17) and others (18) in the 
outcoming immune response. Furthermore, recent 
studies have evidenced the effect of particle size 
(19) and the strength of interaction of CpG ODN 
loaded particles (20, 21) in the immune-
stimulatory activities of particulate based vaccines 
co-delivering antigen and CpG ODN. 
 In this work, we evaluate the resulting 
immune response elicited by co-encapsulated 
CpG sequences and ovalbumin (OVA). The MP 
were prepared with two types of PLGA, 502 and 
756, very different in terms of molecular weight 
and hydrophilicity (22). The optimal CpG and 
OVA encapsulation was achieved by the 
assistance of the cationic lipid 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP) and our 
Total Recirculation One Machine System 
(TROMS) methodology. This approach was based 
on previous work that strengthened the necessity 
of incorporating positive molecules in MP 
composition (23) and the suitability of TROMS 
method to encapsulate compounds into MP with 
efficiency and without affecting their integrity 
(24).  
 
MATERIAL AND METHODS 
 
Preparation of OVA and/or CpG MP 
MP were prepared using a W1/O/W2 emulsion 
(water-in oil-in water) and solvent evaporation 
technique by TROMS (23, 24). Briefly, 50 mg 
(4% w/v) of 12-KDa PLGA 50:50 or 98-KDa 
PLGA 75:25 (PLGA 502 and 756, respectively; 
Boehringer Ingelheim Gmbh, Germany) were 
dissolved in a solution of dichloromethane 
containing DOTAP (1% w/w with respect to the 
polymer; Avanti Polar Lipids Inc, USA). This 
amount of DOTAP corresponds with a ratio N/P 
1, defining this parameter as the molar relation of 
amine groups in the cationic molecule, which 
represent the positive charges, to phosphoric 
groups in the oligonucleotide, which represent the 
negative charges. This solution was injected under 
a turbulent regime (50 mL/min) onto the inner 
aqueous phase using a needle with a diameter of 
0.17 mm. This aqueous phase was composed by 
Pluronic
®
 F68 (250 µL, 6% w/v) containing OVA 
(3 mg; Sigma-Aldrich, USA) and/or CpG 
sequences (300 nmol, #1826, 5`-3`: 
tccatgacgttcctgacgtt; Coley Pharmaceutical 
Gmbh, Germany), depending on the formulation. 
Then, this W1/O emulsion was forced to circulate 
through the system (2 min) to homogenize the 
droplet size. After that, the first emulsion was 
injected onto a solution of PVA (7.5 mL, 0.5% 
w/v) in the same conditions as the initial 
emulsion. This resulted in the formation of a 
double emulsion, which was further homogenized 
by circulation through the system for 4 min. 
Afterwards, the W1/O/W2 emulsion was stirred to 
evaporate the organic solvent and allow the 
formation of the MP. Later, MP were collected by 
centrifugation (20 min, 27100  g) and washed 
twice with deionised water, and then lyophilized. 
 Empty MP were prepared in the same way as 
described above but without including either 
OVA or CpG sequences in the inner aqueous 
phase. 
 
Microparticle characterization 
MP size was determined by laser diffractometry 
using a particle size analyzer (Mastersizer S laser 
sizer, Malvern Instruments, UK) (23). The mean 
size was expressed as the volume mean diameter 
(D[4,3]) in micrometers (m). The Sauter 
diameter (D[3,2]) was also determined and the 
polydispersity was expressed as the ratio of 
D[4,3]/D[3,2]. Zeta potential was assessed by 
laser Doppler velocimetry in a Zetasizer Nano ZS 
(Malvern Instruments, UK) (23). The 
measurements were carried out diluting the 
samples in distilled water at room temperature 
(RT). The yield of the preparation was expressed 
as the percentage (%) of the initial amount of 
polymer which formed lyophilized MP. Besides, 
the shape and morphology of the MP were 
evaluated by scanning electron microscopy. 
Freeze-dried MP were mounted on double-faced 
adhesive tape on metal stubs, coated with gold to 
a thickness of 16 nm (Emitech K550; Quorum 
Technologies, UK) and further the observation 
was made by scanning electron microscopy (Zeiss 
DSM 940 A, Germany) with a digital imaging 
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capture system (Point Electronic GmBH, 
Germany). 
 The OVA content of MP was determined 
using the MicroBCA protein assay (Thermo 
Fisher Scientific, USA), following manufacturer`s 
instructions, as previously described (23). Briefly, 
freeze-dried MP were resuspended in NaOH 0.1 
N (5 mg/mL) and maintained under magnetic 
stirring overnight at RT. The resulting suspension 
was centrifuged (20 min, 27100  g) and the 
supernatant was incubated with the MicroBCA 
reagent for 2 h at 37ºC. The colorimetric reaction 
was measured in a spectrophotometer (iEMS 
Reader MF; Thermo Fisher Scientific, USA) at 
562 nm and compared with the absorbance data 
obtained with non-encapsulated OVA. For this 
purpose, control calibration curves (1.5-50 
g/mL) were prepared using OVA dissolved in 
NaOH 0.1 N. 
 CpG oligonucleotide containing MP were 
similarly incubated with NaOH 0.1 N overnight at 
RT. The amount of CpG sequences was estimated 
fluorimetrically (PerkinElmer LS 50B 
Luminiscence Spectrometer, USA) based on the 
fluorescence measured at 522 nm after the 
incubation of the samples for 10 min with 
Oligreen

 ssDNA Quantitation reagent 
(Invitrogen, USA), as recommended by the 
manufacturer`s instructions. CpG oligonucleotide 
in solution was dissolved in TE buffer (Tris-HCl 
200 mM, EDTA 20 mM, pH 7.5) and incubated 
with the fluorescent reagent to perform a 
sigmoidal-fitted calibration curve (0.05-1.5 
g/mL) (23).  
 The encapsulation of the OVA and CpG was 
expressed as the amount of molecule per 
milligram of MP. Besides, the entrapment 
efficiency was estimated as the ratio (%) between 
the loaded and the initial quantity of OVA and 
CpG sequences added to the formulation, taking 
into account the yield of the fabrication of the 
MP. 
 
In vitro release study  
MP (5 mg) containing OVA and/or CpG 
oligonucleotide were suspended in phosphate 
buffered saline (PBS, 1 mL, pH 7.4) in eppendorf 
tubes (25). The suspension was gently shaken 
under rotating agitation at 37 ºC. At various time 
intervals, the supernatant was removed after 
centrifugation (20 min, 27100  g) and replaced 
with fresh medium. In the supernatants, the 
amount of OVA and CpG sequences were 
determined as described above. Empty MP were 
used as controls and subjected to the same 
procedure. Release data were expressed as the 
cumulative percentage of the protein and the 
oligonucleotide released at each time in 
comparison with the content of these molecules in 
the MP versus the time. 
 
Structural integrity and antigenicity of the 
entrapped OVA 
The structure and the antigenicity of OVA was 
analysed after MP preparation and after its in 
vitro release using Coomassie Brilliant Blue stain 
and Western-blot. Briefly, OVA MP (5 mg) were 
suspended in dichloromethane overnight at 4 ºC. 
Then, the organic solvent was evaporated with 
nitrogen and the pellet was suspended in 
electrophoretic sample buffer (Tris-HCl 62.5 mM 
(pH 6.8), 10% glycerol, 2% SDS, 5% -
mercaptoethanol and 0.05% bromophenol blue). 
Afterwards, the sample was centrifuged (10 min, 
2300  g) to remove any polymeric residues and 
boiled during 10 min to separate possible OVA 
degraded fragments. 
 Samples were analysed by using 15% 
acrylamide gels with the discontinuous buffer 
system of Laemmli (26). Then, gels were stained 
with Coomasie Brilliant Blue R-250 (27) or 
subjected to Western-blot as described previously 
(28). Immunoglobulin G against OVA from 
mouse (Nordic Immunology, Netherlands) was 
used as primary antibody whereas horseradish 
conjugated rabbit anti-IgG and 4-chloro, 1-
naphtol were used as secondary antibody and 
chromogen, respectively. 
 
Integrity of CpG sequences 
The integrity of CpG oligonucleotide loaded or 
released from the MP was evaluated by the 
determination of its melting temperature (29). On 
one hand, MP (5 mg) containing CpG sequences 
were degraded with NaOH 0.1 N under magnetic 
shaking overnight to extract the oligonucleotide. 
On the other hand, supernatants obtained after 38 
days of incubation in PBS in the release studies 
were used directly to measure the integrity of the 
CpG released from the particles. Both solutions 
were adjusted to an optimal concentration of 4 
ng/L and incubated with the sense 
oligonucleotide (5`-3`: AACGTCAGCAACG-
TCATGGA; Thermo Fisher Scientific, USA) in 
the presence of SYBR Green

 I nucleic acid gel 
stain (Invitrogen, USA) diluted in buffer Tris-HCl 
100 mM (pH 8.9), NaCl 100 mM and MgCl2 14 
mM. In this context, sense and antisense 
oligonucleotide tended to form a double strand, 
which enclosed the SYBR Green

 I nucleic acid 
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gel stain. This compound emits fluorescence 
when it is associated to the duplex and its signal is 
proportional to the hybridization capacity of the 
oligonucleotides. This parameter was measured in 
a fluorescence temperature cycler (Lightcycler, 
Roche Diagnostics GmbH). Precisely, the duplex 
was heat at 0.2 ºC/s until 95 ºC measuring the 
fluorescence signal during the process and 
obtaining a melting curve. For improved 
visualisation of the melting temperature or Tm 
(temperature at which 50% of the oligonucleotide 
is forming a double strand) the initial data were 
derived to obtain melting peaks (fluorescence (F) 
versus temperature (T) by plotting the negative 
derivative of fluorescence over temperature 
versus temperature; (-dF/dT) versus T). 
 
Bone marrow-derived dendritic cells (BMDC) 
generation and activation 
C57BL/6 mice (8 weeks, female) were obtained 
from Harlan Interfauna Ibérica (Spain) and 
housed in pathogen-free conditions according to 
the guidelines of the Ethical Committee of the 
University of Navarre in line with the European 
legislation on animal experiments (86/609/EU). 
As previously described (30), femurs and tibia 
were extracted after animal cervical dislocation 
and the bone marrow was flushed out using a 26 
gauge needle with supplemented RPMI 1640 
medium (0.1% -mercaptoethanol 50 mM, 0.5% 
sodium pyruvate 100 mM, 1 IU/mL penicillin, 1 
g/mL streptomycin and 10% v/v foetal bovine 
serum; all from Invitrogen, USA). In the cell 
suspension, erythrocytes were lysed and 
lymphocytes and granulocytes were deplected by 
incubation with different antibodies against CD4, 
CD8, Ly-6G/Gr1 and CD45R and rabbit 
complement. The final suspension was grown at 
1×10
6
 cells/mL in 6-well plates (2 mL/well) with 
RPMI 1640 medium containing IL-4 and GM-
CSF (25 ng/mL; PrepoTech EC, USA). Once 
confirmed that the bone marrow-derived dendritic 
cells (BMDC) precursors were immature dendritic 
cells (DC; CD11c+ subset), two-thirds of the 
medium was replace with fresh medium 
containing GM-CSF and IL-4 at days 2, 4, 5 and 
6. The activation of BMDC was evaluated by IL-
12 production and up-regulation of surface 
maturation markers. After 18 h incubation with 2 
g/ml CpG associated to MP, supernatants were 
collected for IL-12 determination using a 
commercial ELISA kit. The cells were washed, 
pre-incubated with a rat antiCD16/CD32 mAb 
(2.4G2 clone) and stained with antiCD40-PE 
(3/23 clone) and anti-CD86-PE (GL1 clone) or 
appropriate isotype control antibodies and 
analysed by flow cytometry (FACs Calibur, BD). 
All antibodies and ELISA recombinant standard 
were from BD Pharmingen. 
 Untreated BMDC, free CpG (2 g/mL), LPS 
(1g/mL) and unloaded MP were used as controls 
and subjected to the same experimental 
conditions.  
 
Mice immunization 
Eight weeks old female BALB/c mice, obtained 
from Harlan Interfauna Ibérica (Spain) and 
housed in specific pathogen free conditions, were 
used for immunization. The experiments were 
performed in compliance with the regulations of 
the Ethical Committee of the University of 
Navarre in line with the European legislation on 
animal experiments (86/609/EU). 
 Mice (n=8) were immunized by intradermal 
route twice (days 0 and 14) with 10 g OVA in 
the following combinations (23): i) OVA in 50 L 
of PBS; ii) OVA and CpG sequences (10 g, the 
mean between the administered amount of CpG in 
PLGA 502 and 756 MP) physically mixed; iii) 
OVA loaded MP (OVA PLGA 502 and OVA 
PLGA 756); iv) CpG loaded MP (CpG PLGA 502 
and CpG PLGA 756); v) OVA and CpG co-
encapsulated into MP (OVA CpG PLGA 502 and 
PLGA 756) and vi) OVA emulsified with 
complete Freund´s adjuvant (CFA). PBS and CpG 
sequences in solution were administered as 
controls.  
 Blood samples were collected from the retro-
orbital plexus at day 49 after the first 
immunization. Samples were centrifuged and the 
resulting sera were pooled within each 
experimental group. Finally, the sera were diluted 
1:10 in PBS and stored at –80 ºC until assayed by 
ELISA. 
 
Measurement of anti-OVA antibody levels in 
serum  
OVA-specific antibodies in the mouse serum 
were detected using an indirect ELISA (23). The 
experiment was carried out as follows: 96-well 
plates were coated with 1 g OVA in 100 L of 
carbonate-bicarbonate buffer (pH 9.6) and 
maintained overnight at 4 ºC. After being washed 
in PBS containing 0.05% Tween

 20 (PBS-T20), 
test samples at different dilutions were added to 
wells and incubated during 4 h at 37 ºC. Then, 
unbound antibody was eliminated prior to the 
incubation with goat anti-mouse IgG1 or IgG2a 
horseradish peroxidase conjugate (diluted 1:1000 
in PBS-T20; Nordic Immunology, The 
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Netherlands). Following a 1 h incubation at 37 ºC 
and five washing steps, 100 L of chromogen and 
substrate solution (2, 2′-Azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid and 
hydrogen peroxide) was added. After a final 
incubation of 30 minutes under agitation, the 
absorbance was measured at 405 nm by an iEMS 
Reader MF (Thermo Fisher Scientific, USA). 
Data were expressed as antibody titre, which is 
defined as the reciprocal of a serum dilution 
whose optical density was equal or above 0.2 than 
blank samples reading the absorbance at 405 nm, 
starting from sample dilution 1:40. 
 
Cytokine assay  
On day 13 after first immunization (and before 
the second one), three mice in each group were 
sacrificed and spleens were removed and placed 
in supplemented RPMI 1640 medium under 
sterile conditions (30). Each spleen was smashed 
and cells within experimental groups were pooled 
in one flask. The cellular suspension was 
centrifuged for 10 min at 400  g, the supernatant 
discarded and the pellet washed twice with PBS. 
The splenocytes were suspended in lysis buffer 
(NH4Cl 0.15 M, KHCO3 10 mM, EDTA 0.1 mM) 
for 2 min to eliminate erythrocytes and refilled 
with RPMI 1640 to stop the reaction. This 
suspension was centrifuged (5 min, 400  g) and 
the pellet was resuspended in supplemented 
RPMI 1640 medium. The lymphocyte suspension 
was added to 96-well round bottom microtitre 
plates (4 × 10
5
 cells/well) along with test antigen 
(20, 80 and 160 g OVA/ml in a final volume of 
200 L per well). Negative (wells without 
antigen) and positive (wells containing 2 g/mL 
concanavalin A) controls were used. The culture 
supernatants were collected for cytokine assay 
(IFN- and IL-4; Pharmingen, BD Biosciences, 
USA) at 48 h after the stimulation and kept frozen 
at -80 ºC until testing.  
 
RESULTS 
 
Characterization of OVA and/or CpG MP 
Table 1 summarizes the physico-chemical 
characteristics of PLGA 502 and 756 MP 
prepared by TROMS. All the batches displayed a 
uniform size distribution of around 1 m, 
independently on the polymer and OVA and/or 
CpG content, as revealed laser diffraction. 
Whereas the zeta potential of OVA loaded MP 
was slightly positive (around 10 mV), CpG 
encapsulated or co-encapsulated MP exhibited a 
slight negative zeta potential. Irrespective of 
polymer, OVA and CpG loading efficiency were 
very high and increased when both were co-
encapsulated into the same microparticle 
formulations. So, OVA encapsulation efficiency 
increased from 20% (OVA loaded MP) to 50% 
(OVA and CpG loaded MP), whereas CpG 
loading was always close to 80%. From scanning 
electron microscopy studies (Figure 1), MP were 
found to be spherical, homogenous, without pores 
and with similar sizes than those obtained by laser 
diffractometry. Finally, the yield of the 
fabrication process was 70%. 
 
 
Table 1: Physicochemical characterization of MP containing OVA and/or CpG sequences and prepared using 
DOTAP to form a complex with the oligonucleotide. Data are expressed as mean ± SD (n=3). 
Polymer Formulation 
D[4,3] 
(m) 
Polydispersity 
(D[4,3]/D[3,2]) 
Zeta potential 
(mV) 
OVA loading 
(g/mg MP) 
CpG loading 
(g/mg MP) 
502 
OVA 1.4±0.5 1.2±0.1 8.7±0.7 22.8±1.0 - 
CpG 1.0±0.2 1.8±0.9 -6.8±7.3 - 45.0±3.3 
OVA CpG 2.0±0.4 3.6±0.4 -12.4±6.10 42.0±3.9 45.2±6.5 
756 
OVA 0.9±0.5 1.2±0.05 10.6 14.9±3.3 - 
CpG 1.4±0.8 1.2±0.6 -3.0 - 50.3 
OVA CpG 1.7±0.5 2.7±2.1 -5.8±2.0 62.5±8.7 51.1±3.6 
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In vitro release of OVA and CpG sequences 
from the MP 
Figure 2 show the release of OVA and CpG 
sequences from MP. The antigen release was 
higher for OVA containing MP (34% and 16% for 
PLGA 756 and 502 MP, respectively, at day 38) 
than for antigen and oligonucleotide loaded MP 
(11% and 3% for PLGA 756 and 502 MP, 
respectively, at day 38) although, in all the cases, 
the release was slow throughout the experiment 
(Figure 2a). The rate was even slowed down in 
the presence of co-encapsulated CpG sequences. 
Also, the release of CpG oligonucleotides was 
sustained but slow until the end of the experiment 
(Figure 2b). 
 
OVA structural analysis and antigenicity and 
CpG integrity 
OVA containing MP were analysed by Coomassie 
Brilliant Blue staining and immunoblotting to 
discard any negative consequences on both 
structural integrity and antigenicity of OVA. After 
gel staining and immunoblotting, no differences 
were detected between microencapsulated OVA 
and the native protein in terms of structure or 
molecular weight (Figure 3). In consequence, the 
integrity and the antigenicity of OVA were not 
damaged along the preparation of any of the 
formulations. When studying these parameters in 
samples from release experiments, the structure 
and the antigenicity of the protein were unaltered 
in any of the formulations assessed (data not 
shown). 
  The results for the analysis of the Tm 
values after incubation of the oligonucleotide 
extracted from the MP with its complementary 
strand and a fluorescent compound indicated that 
all the tested samples displayed identical values 
for the Tm (within the limits of experimental error; 
±1 ºC) than the one observed for the 
oligonucleotide in PBS (59.7 ºC) (Figure 4). CpG 
released from MP after 38 days was analysed in 
the same way in order to evaluate if the 
microacidic environment created by the 
degradation of the PLGA along the time could 
alter the integrity of the oligonucleotide released. 
Similarly, the melting temperature for released 
oligonucleotide was not altered throughout the 
time in any of the tested formulations (data not 
shown). In consequence, the integrity of the 
oligonucleotide was intact despite the degradation 
of the polymer, the organic solvent or the shearing 
forces used in the preparation of the MP. 
 
 
Table 2: Sera antibody (IgG2a and IgG1 isotypes) 
response to OVA measured by indirect ELISA on sera 
from BALB/c mice intradermically immunized (days 0 
and 14) with 10 g of OVA alone, combined with 
adjuvants (CpG sequences and CFA) or encapsulated in 
MP. The antibody titre is defined as the reciprocal of a 
serum dilution whose optical density was equal or 
above 0.2 than blank samples reading the absorbance at 
405 nm, starting from sample dilution 1:40.   
Treatment 
IgG2a 
titre 
IgG1 
titre 
IgG2a/IgG1 
OVA 0 9 0.00 
OVA + CpG 9 10 0.90 
OVA PLGA 502 0 3 0.00 
OVA CpG PLGA 502 4 8 0.50 
OVA PLGA 756 7 13 0.54 
OVA CpG PLGA 756 0 5 0.00 
OVA + CFA 11 19 0.57 
 
      
 
 
Figure 1. Scanning electron microscopy of lyophilized 
OVA (top) and OVACpG (bottom) loaded MP 
prepared by TROMS. 
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Figure 2. in vitro release of (a) OVA and (b) CpG 
sequences incubated under rotating agitation in PBS at 
37 ºC. Data are expressed as the cumulative release 
(%) versus time (days). Data represent mean ± SD of 
three independent experiments. 
 
Antibody response 
Table 2 shows the IgG1 and IgG2a profile 
induced in experimental animals after double 
immunization with all the tested treatments. The 
encapsulation of the antigen into MP resulted in 
different outcomes depending on the polymer. For 
OVA PLGA 502, the immune profile was not 
modified (IgG2a/IgG1=0.00) comparing with the 
free OVA (IgG2a/IgG1=0.00) but the antibody 
production (defined as the sum of IgG1 and 
IgG2a antibody titres) was decreased (from 9 
titres for OVA in solution to 3 titres for OVA 
PLGA 502). In the case of OVA PLGA 756, the 
elicited immune profile was more balanced 
between the Th1 and Th2 responses 
(IgG2a/IgG1=0.54) achieving a most potent 
stimulation of the antibodies production (20 titres 
of IgG1 and IgG2a) than the OVA control group.  
 
Table 3: Cytokine production (IFN- and IL-4) by 
splenocytes obtained from BALB/c mice 13 days 
after intradermal immunization with 10 g of OVA 
alone, combined with adjuvants (CpG sequences 
and CFA) or encapsulated in MP. The resulting 
splenocytes suspensions were in vitro re-estimulated 
with 80 g OVA/mL for 48 h to analyse IFN- and 
IL-4 production (pg/mL).   
Treatment 
IFN- 
(pg/mL) 
IL-4 
(pg/mL) 
IFN-
/IL-4 
OVA 422±57 65±21 6 
OVA + CpG 3459±241 111±76 31 
OVA PLGA      
502 
2278±1641 48±13 47 
OVA CpG 
PLGA 502 
1137±464 8±11 142 
OVA PLGA 
756 
685±48 12±1 57 
OVA CpG 
PLGA 756 
0 39±36 0 
OVA + CFA 3807±1474 62±41 61 
 
2     3     4     5
MW (kDa)
20.1
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45
66
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2     3     4    51
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Figure 3: Study of the integrity of OVA after 
encapsulation in MP using TROMS. (a) SDS-PAGE 
stained for proteins (Coomasie Brilliant Blue R-250) 
and (b) Western-blot analysis with an anti-OVA 
immunoglobulin G and horseradish conjugated anti-
IgG from rabbit. Lane 1: molecular marker; 2: OVA 
PLGA 502; 3: OVA CpG PLGA 502; 4: OVA PLGA 
756; 5: OVA CpG PLGA 756.  Load was the 
equivalent to 10 g OVA/well. 
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 Whereas the administration of a solution of the 
antigen induced a strong Th2 response 
(IgG2a/IgG1=0.00), the inclusion of CpG 
sequences resulted in a bias between IgG2a and 
IgG1 antibodies production (IgG2a/IgG1=0.90). 
Regarding the co-encapsulation, OVA CpG 
PLGA 502 displayed a balance between IgG1 and 
IgG2a responses but the potency and the specific 
antibody ratio (12 titres of IgG1 and IgG2a and 
IgG2a/IgG1=0.50) were inferior than the one 
obtained after the administration of CpG 
sequences and OVA in solution (19 titres of total 
IgG and IgG2a/IgG1=0.90). PLGA 756 
containing both OVA and CpG sequences were 
not able to elicit a biased response 
(IgG2a/IgG1=0.00) and the strength of the 
antibodies production was reduced (5 titres of 
IgG1 and IgG2a) in comparison with the physic 
mixture of both the antigen and the 
oligonucleotide. 
 
 
 
Figure 4: Fluorescence melting curve analysis of MP 
containing CpG sequences after extracting the 
oligonucleotide from the particles with NaOH 0.1N 
overnight. Data are expressed plotting the negative 
derivative of fluorescence over temperature versus 
temperature. Free oligonucleotide () was subjected 
to the same experimental conditions and used as 
control. CpG PLGA 502 (), OVA CpG PLGA 502 
(●), CpG PLGA 756 () and OVA CpG PLGA 756 
(○).  
 
 
The expression of CD40 and CD86 and the 
production of IL-12 (a pro-Th1 cytokine) were 
measured in order to evaluate the effect of 
microencapsulation on the immunopotency of 
CpG. CD40 and CD86 surface markers, expressed 
as percent or mean fluorescent intensity (MFI) 
relative to non-stimulated DC, and IL-12p70 
production are shown in Figure 5a and 5b, 
respectively. It can be observed that either free or 
associated to MP, CpG motifs induced similar 
level of DC maturation. No signs of DC activation 
were observed after cell incubation with unloaded 
PLGA MP, irrespective of polymer. 
 The encapsulation of OVA resulted in a less 
strong Th2 for PLGA 502 and in bias between 
Th1 and Th2 responses for PLGA 756 compared 
with the antigen in solution. Also, it can be 
observed that the addition of CpG sequences to 
the OVA loaded MP result in a benefit only for 
PLGA 502 (although not reaching to the potent 
immune response elicited by OVA and CpG in 
solution) whereas PLGA 756 containing CpG 
sequences were not able to improve the 
immunological balance obtained by OVA PLGA 
756. Finally, the co-encapsulation of both 
molecules into particles did not provide any 
immunological benefit if comparing with the 
physic mixture. 
 
Cellular immune response 
The determination of IFN- and IL-4 (Table 3) 
indicated which subset of Th cell population was 
predominant after one single shot by intradermal 
route with the treatments described above. The 
production of IFN- displayed an enhancement, 
moderate for OVA PLGA 756 (685±48 pg/mL) 
and very strong for OVA PLGA 502 (2278±1641 
pg/mL) in comparison with the result obtained 
from splenocytes treated with OVA in solution 
(422 pg/mL). Regarding the IL-4 level, these both 
treatments were able to diminish the production of 
this pro-Th2 cytokine (12±1 and 48±13 pg/mL for 
PLGA 756 and PLGA 502, respectively, versus 
65±21 pg/mL for OVA in solution). Altogether, 
IFN-/IL-4 ratio was more biased towards Th1 for 
OVA MP than for the antigen in solution (47 and 
57 for OVA PLGA 502 and OVA PLGA 756, 
respectively, versus 6 for OVA). 
 As it was expected, the mixture of OVA and 
CpG sequences induced a high production of IFN-
 (3459±241 pg/mL) accompanied with an 
increase in the production of IL-4 (111±76 
pg/mL). The encapsulation of both molecules into 
MP was not able to achieve higher levels of IFN- 
with none of the polymers (1037±464 and 0 
pg/mL for PLGA 502 and PLGA 756, 
respectively) but the IL-4 levels decreased 3-14 
fold (8±11 and 35±36 pg/mL for PLGA 502 and 
PLGA 756, respectively) the production observed 
in OVA plus CpG sequences treated mice. 
Moreover, IFN-/IL-4 ratio for OVA CpG PLGA 
502 (IFN-/IL-4=142) was higher than the one 
observed with OVA and CpG sequences in 
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solution (IFN-/IL-4=31) or OVA loaded MP. 
Despite of the decrease of IL-4 production after 
immunization with OVA CpG PLGA 756, the 
lack of IFN- production did not generate any 
modification in the Th1/Th2 immune balance. 
 Therefore, OVA loaded MP were able to 
generate more Th1 biased responses than the 
administration of the antigen in solution. 
However, the fact of co-encapsulation did not 
lead to an enhancement in the Th1 response but 
displayed a potent decrease of the pro-Th2 
cytokine in comparison with the physical mixing 
of the antigen and the immunostimulatory 
sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: (a) Phenotypic maturation and (b) IL-12 production after 24 h incubation of BMDC with 2 g/mL CpG, 
given either in solution or loaded into PLGA 502 or PLGA 756 MP. BMDC untreated (DC), receiving LPS (1 g/mL), 
unloaded and OVA loaded PLGA 502 or PLGA 756 MP were included as controls. In (a) the bars perform the increase 
in percentage of CD40+ and CD80+ cells and Mean Fluorescence Intensity (MFI), calculated respect to control group 
(untreated DC). (a) Data of one experiment representative of the results from three independent experiments (b) Data 
represent mean ± SD of two independent experiments. 
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DISCUSSION 
 
In this study we evaluated the immune response 
induced in BALB/c mice after intradermal 
administration of CpG oligonucleotides (1826, B 
type) co-encapsulated with a model antigen 
(OVA) into 1 m DOTAP PLGA MP. Very high 
OVA and CpG loadings into non-charged PLGA 
502 or PLGA 756 MP that prolonged their release 
over 38 days were achieved (see Table 1 and 
Figure 2) by using a previously described new 
double emulsion solvent evaporation method 
TROMS (23, 24). 
 The rational approach of the current study is 
that the CpG particulate delivery could enhance 
the adjuvanticity of CpG ODN by selective 
targeting to APC and enhanced interaction with 
their endosomal receptor TLR9 (31). In addition, 
their co-encapsulation with an antigen into the 
same particle guarantees their uptake by the same 
APC with the most specific immune activation. 
Several CpG and antigen delivery systems 
supporting this approach have been evaluated 
with success (32-36). 
 In this work, the optimal CpG encapsulation 
with prolonged release over 38 days was achieved 
by blending PLGA with the cationic lipid DOTAP 
into the organic phase during the process of 
microparticle preparation by TROMS (Table 1). 
CpG oligonucleotides were added into the inner 
aqueous phase. The negative influence of DOTAP 
in the OVA loading into MP (27% encapsulation 
efficiency vs. 40% when MP were prepared in 
absence of DOTAP, data not shown) and the 
slightly positive zeta potential values of OVA 
DOTAP MP suggest a preferential disposition of 
the cationic lipid in the interfaces of the double 
emulsion, where amphiphilic OVA also tended to 
localise (Table 1). On the contrary, the return of 
OVA loading to normal levels and the negative 
zeta potential observed in formulations that co-
encapsulated the antigen with CpG ODN suggest 
the formation of hydrophobic ion-pair 
CpG:DOTAP complexes that are entrapped into 
the inner aqueous phase, allowing consistently 
high CpG encapsulation efficiencies and very 
slow and incomplete CpG release, irrespective of 
PLGA polymer. 
 In spite of CpG very slow and incomplete 
release, in vitro after 24 h incubation CpG loaded 
MP up-regulated CD40 and CD86 expression 
(Figure 5a) and activated BMDC for IL-12 
production (Figure 5b) at the same level than free 
CpG ODN. Although a body of previous works 
found an enhancement in this cytokine secretion 
with the loading of CpG in delivery systems (37), 
others authors established more complex 
relationships between CpG physical presentation 
to cells and immunostimulatory properties. So, 
whereas soluble CpG trigger robust IL-12 
production on CD8+ DC, CpG-DOTAP target in 
addition CD11c+ DC and non-DC cell types (38). 
The complexation of CpG with DOTAP also 
produced a modification in ODN intracellular 
trafficking prone to increase IFN- production 
(39). Therefore, particle parameters such as size 
critically affected the immuno-stimulatory 
activities of CpG. In human blood cells, 
microencapsulated CpG preferentially target 
macrophages and increase TNF- production 
whereas nanometric particles enhanced the uptake 
of CpG by pDC and the production of IFN- (40). 
In vitro, in a DC-like cell line, it was observed 
that CpG bound to polystyrene nanoparticles 
stimulated the production of IL-6 and IFN- 
while those bound to MP produced only IL-6 
(19). In another report, multimeric CpG ODN 
type A or CpG-B complexed with polymixin MP 
localize to endosomes and leads exclusively to 
IFN- production from pDC whereas monomeric 
forms CpG B ODN rapidly translocate to 
endosomes, losing capability to stimulate IFN- 
production and gaining in APC maturation 
activity and production of inflammatory cytokines 
(41).  
 The localization of CpG ODN in the particles 
also played a prominent role in their 
adjuvanticity. So, the co-delivery of both CpG 
and the antigen MenB into the same PLGA 
particle produced stronger humoral immune 
responses that the co-administration of particles 
loading separately the antigen and CpG ODN 
(20). Furthermore, PLGA MP with adsorbed, but 
not encapsulated, CpG ODN mediated a 
significant increase in the percentage of IFN- 
secreting CD8+ T cells. The low immunogenicity 
of CpG ODN co-encapsulated with the antigenic 
peptide SIINFEKL within PLGA MP was well-
correlated with the low amounts of CpG released 
from the particles (21). 
 In contrast with the ability of 
microencapsulated CpG to stimulate IL-12 
production from DC in vitro (IL-12 is a potent 
Th1 promoting cytokine), the microparticulate 
delivery of CpG ODN with OVA induced a lower 
Th1 cell response (measured as IFN- production) 
that either free CpG simply co-administered with 
the antigen or the OVA microencapsulated alone. 
The results were affected by the polymer type 
(Table 3). Whereas OVA or OVA and CpG 
entrapped into PLGA 502 MP induced IFN- 
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production (Th1 response), the antigen 
encapsulated or co-encapsulated with CpG into 
PLGA 756 MP elicited negligible levels of this 
cytokine. Therefore, antibodies levels induced by 
MP containing OVA and CpG ODN were lower 
to that induced by the antigen and CpG ODN in 
solution, in agreement with the lower T cell 
responses observed (Table 2). Other authors have 
also reported that the particulate delivery of CpG 
tended to decrease the antibody response when 
compared with CpG simply co-administered with 
the antigen (33, 42). Whereas CpG given in saline 
are accessible to B cells directly (43), CpG ODN 
needs to be released from MP to stimulate non-
phagocytic B cells. In the current study, the 
fractions of CpG released from MP could be sub-
optimal for B cell stimulation as a consequence of 
the very slow release observed.  
 It is known that polymers can modulate the 
type of immune response addressed to the carried 
antigens. In this study, whereas OVA alone or 
OVA loaded into PLGA 502 MP triggered IgG1 
antibody response, OVA microencapsulated into 
PLGA 756 displayed higher antibody titres, 
increased production of IgG2a antibodies (Table 
2) and higher IFN-/IL-4 ratio (Table 3). 
Furthermore, the antibodies production was 
enhanced as a consequence of the CpG co-
encapsulation and it was observed a shift of 
isotype profile only in mice immunized with CpG 
loaded PLGA 502. OVA CpG 756 elicited only 
low IgG1 (Table 2) and IFN- production (Table 
3). Both, the highest antibodies production and 
IFN-/IL-4 ratio, were observed in mice 
immunized with PLGA 502 MP loading OVA and 
CpG. In agreement with this finding, only OVA-
sensitized mice treated with MP co-encapsulating 
OVA plus CpG were totally protected from death 
by anaphylaxis (44).  
 Overall, this work introduces that polymer 
affects the adjuvanticity of microencapsulated 
CpG ODN and antigen. However, the differences 
between the immune response elicited by PLGA 
502 and PLGA 756 cannot be ascribed to any 
significant differences either in the amount and 
rate of antigen and CpG released from MP or in 
vitro stimulatory effect in BMDC. The release of 
antigen and CpG should be analysed after 
phagocytic uptake of MP by APC at the 
intracellular level. Furthermore, although in vitro 
free or encapsulated CpG similarly stimulated 
DC, in vivo the polymer could also modulate the 
complement activation or inflammation produced 
by the particles at the site of administration, keys 
in their immunoadjuvant properties (3). In this 
context, further analysis using different molecular 
weight of PLGA and using different polymers 
should be performed in order to conclude a 
general effect of the polymeric MP on the in vivo 
activity. 
 Polymeric particles perform an excellent and 
extremely versatile platform for designing vaccine 
adjuvants with the required characteristics, 
allowing fine tuning over the variables that are 
important in optimizing an effective vaccine 
delivery system. However, there are big gaps to 
fill in the influence of particles characteristics in 
the out coming immune response to fully exploit 
the potential of particulates as vaccine adjuvants. 
Multiple papers described the goodness and great 
versatility of PLGA microspheres as adjuvants for 
vaccination. However, only PLGA MP with 
adsorbed HIV-1 DNA underwent Phase I clinical 
testing in the USA (45). In the lead, either CpG, 
monophosphoryl lipid A and imiquimod (TLR 
agonists) or other particulate adjuvants as Alum 
or the emulsions MF59

 are currently approved 
for use in human vaccines. In general, particles 
enhance antibodies production. However, they 
produced Th0 (MF59

) or poor Th2 (Alum) 
skewed immune responses (46). On the contrary, 
the triggering of TLR tends to induce a strong 
Th1-biased helper T-cell response and cytotoxic T 
lymphocyte activation. In order to find their niche 
in this scenario, MP should set their advantages 
and particularities, if any, in terms of both 
efficacy and security through their systematic 
comparison with currently approved adjuvants, 
especially those particulates in nature (Alum and 
MF59

). 
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